Suppr超能文献

基于肿瘤扩散的 T2 期胆囊癌的合理治疗策略。

Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.

机构信息

Department of Surgery, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga 849-8501, Japan.

出版信息

World J Gastroenterol. 2010 Jul 28;16(28):3567-72. doi: 10.3748/wjg.v16.i28.3567.

Abstract

AIM

To evaluate the adequacy of surgical treatment of T2 gallbladder carcinoma (GBCa) according to tumor spread in the subserosal layer.

METHODS

A series of 84 patients with GBCa were treated at Saga University Hospital, Japan between April 1989 and October 2008. The tumor stage was graded according to the TNM staging for GBCa from the American Joint Committee on Cancer Manual 6th edition. Tumor staging revealed 30 patients with T2 tumors. T2 GBCa was divided into three groups histologically by the extent of tumor spread in the subserosal layer, using a score of ss minimum (ss min), ss medium (ss med) or ss massive (ss mas).

RESULTS

For ss min GBCa, there was no positive pathological factor and patient survival was satisfactory with simple cholecystectomy, with or without extra-hepatic bile duct resection. For ss med GBCa, some pathological factors, h-inf (hepatic infiltration), ly (lymphatic invasion) and n (lymph node metastasis), were positive. For ss mas GBCa, there was a high incidence of positive pathological factors. The patient group with extra-hepatic bile duct resection with D2 lymph node dissection (BDR with D2) and those with S4a5 hepatectomy had significantly better survival rates.

CONCLUSION

We suggest that radical surgery is not necessary for ss min GBCa, and partial hepatectomy and BDR are necessary for both ss med and ss mas GBCa.

摘要

目的

评估根据胆囊壁固有层肿瘤扩散程度对 T2 期胆囊癌(GBCa)进行手术治疗的充分性。

方法

日本佐贺大学医院于 1989 年 4 月至 2008 年 10 月期间对 84 例 GBCa 患者进行了治疗。肿瘤分期根据美国癌症联合委员会手册第 6 版的 GBCa 的 TNM 分期进行分级。肿瘤分期显示 30 例患者为 T2 肿瘤。通过固有层肿瘤扩散程度的组织学,将 T2 GBCa 分为三组,使用 ss 最小(ss min)、ss 中等(ss med)或 ss 大量(ss mas)评分。

结果

对于 ss min GBCa,无阳性病理因素,单纯胆囊切除术,无论是否行肝外胆管切除术,患者生存均满意。对于 ss med GBCa,存在一些阳性病理因素,如 h-inf(肝浸润)、ly(淋巴侵犯)和 n(淋巴结转移)。对于 ss mas GBCa,阳性病理因素的发生率较高。行肝外胆管切除术加 D2 淋巴结清扫术(BDR 加 D2)和行 S4a5 肝切除术的患者生存明显较好。

结论

我们认为,对于 ss min GBCa,不需要根治性手术,而对于 ss med 和 ss mas GBCa,部分肝切除术和 BDR 是必要的。

相似文献

1
Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.
World J Gastroenterol. 2010 Jul 28;16(28):3567-72. doi: 10.3748/wjg.v16.i28.3567.
4
Surgical treatment of patients with T2 gallbladder carcinoma invading the subserosal layer.
J Am Coll Surg. 2001 May;192(5):600-7. doi: 10.1016/s1072-7515(01)00814-6.
5
Surgical procedure determination based on tumor-node-metastasis staging of gallbladder cancer.
World J Gastroenterol. 2015 Apr 21;21(15):4620-6. doi: 10.3748/wjg.v21.i15.4620.
6
Mode of tumor spread and surgical strategy in gallbladder carcinoma.
Langenbecks Arch Surg. 2002 Oct;387(5-6):222-8. doi: 10.1007/s00423-002-0318-6. Epub 2002 Oct 2.
7
Lymphatic spread of T2 gallbladder carcinoma: Regional lymphadenectomy is required independent of tumor location.
Eur J Surg Oncol. 2019 Aug;45(8):1446-1452. doi: 10.1016/j.ejso.2019.03.038. Epub 2019 Mar 30.
8
"Extended" radical cholecystectomy for gallbladder cancer: long-term outcomes, indications and limitations.
World J Gastroenterol. 2012 Sep 14;18(34):4736-43. doi: 10.3748/wjg.v18.i34.4736.

引用本文的文献

1
2
To Resect or Not to Resect Extrahepatic Bile Duct in Gallbladder Cancer?
J Clin Med Res. 2017 Feb;9(2):81-91. doi: 10.14740/jocmr2804w. Epub 2016 Dec 31.
3
Surgical outcomes and prognostic factors influencing long-term survival in patients with gallbladder cancer.
Korean J Hepatobiliary Pancreat Surg. 2012 May;16(2):59-64. doi: 10.14701/kjhbps.2012.16.2.59. Epub 2012 May 31.
4
Gallbladder cancer: Clinical and pathological approach.
World J Clin Cases. 2014 Oct 16;2(10):515-21. doi: 10.12998/wjcc.v2.i10.515.
6
Role of cholecystectomy and lymph node dissection in patients with T2 gallbladder cancer.
World J Surg. 2013 Nov;37(11):2635-40. doi: 10.1007/s00268-013-2187-2.
7
Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.
J Clin Oncol. 2011 Dec 10;29(35):4627-32. doi: 10.1200/JCO.2010.33.8020. Epub 2011 Nov 7.
8
Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognostic factors in T2 lesions.
Virchows Arch. 2011 Oct;459(4):449-56. doi: 10.1007/s00428-011-1131-9. Epub 2011 Jul 22.

本文引用的文献

3
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.
Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55. doi: 10.1007/s00280-007-0673-7. Epub 2008 Jan 23.
5
Gemcitabine in advanced biliary tract cancers.
Crit Rev Oncol Hematol. 2007 Mar;61(3):230-42. doi: 10.1016/j.critrevonc.2006.04.006. Epub 2006 Dec 8.
7
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
Am J Clin Oncol. 2004 Dec;27(6):565-9. doi: 10.1097/01.coc.0000135924.94955.16.
8
Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer?
Surgery. 2004 Nov;136(5):1012-7; discussion 1018. doi: 10.1016/j.surg.2004.04.032.
9
Phase II study of S-1 in patients with advanced biliary tract cancer.
Br J Cancer. 2004 Nov 15;91(10):1769-74. doi: 10.1038/sj.bjc.6602208.
10
Surgical treatment of gallbladder cancer.
J Gastrointest Surg. 2004 Jan;8(1):83-9; discussion 89. doi: 10.1016/j.gassur.2003.09.022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验